Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Wayne L FurmanElizabeth B McCarvilleBarry L ShulkinAndrew DavidoffMatthew J KrasinChia-Wei HsuHaitao PanJianrong WuRachel C BrennanMichael W BishopSara HelmigElizabeth A StewartFariba NavidBrandon M TriplettVictor SantanaTeresa C SantiagoJacquelyn A HankStephen D GilliesAlice Lin-Tsing YuPaul M SondelWing H LeungAlberto S PappoSara M FedericoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Adding hu14.18K322A to induction chemotherapy improved early objective responses, significantly reduced tumor volumes in most patients, improved end-of-induction response rates, and yielded an encouraging 3-year EFS. These results, if validated in a larger study, may be practice changing.